PACTR202405869934666尚未招募3 期
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-UVB Light Alone in the Treatment of Vitiligo
CLINUVE0 个研究点目标入组 200 人开始时间: 2024年3月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13 Year(s) 至 18 Year(s)（—）
- 性别
- All
入选标准
- •Male and female participants with a confirmed diagnosis of generalized vitiligo in the face and body with T-VASI=0.3 (excluding hands and feet) and F-VASI=0.3 (face does not include scalp, ears, neck or lips)
- •-Stable or active vitiligo diagnosed for at least three months
- •-Aged 12 or more
- •-Fitzpatrick skin types IV-VI
- •-Willing and able to comply with the conditions specified in this protocol and study procedures in the opinion of the Investigator
- •-Providing written Informed Consent prior to the performance of any study-specific procedure
排除标准
- •-Fitzpatrick skin types I-III
- •-Extensive leukotrichia within the vitiligo lesion (over 33%)
- •-Treatment with NB-UVB phototherapy in the last three months prior to phototherapy. A three-month washout period from phototherapy is necessary prior to commencing treatment
- •-Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/ lidocaine or other local anesthetic if used during the administration of the implant
- •-Any other treatment for vitiligo within four weeks prior to the Screening Visit including JAK inhibitors
- •-History of melanoma or lentigo malignacy
- •-History of dysplastic nevus syndrome
- •-Any malignant skin lesions
- •-Any skin disease that may interfere with the study evaluation
- •-Presence of severe hepatic disease or hepatic impairment
- •-Female who is pregnant (confirmed by positive ß-HCG pregnancy test) or lactating
- •-Female of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives or diaphragm plus spermicide or intrauterine device) during the treatment phase (three months) and for a period of three months thereafter – except if abstinence from intercourse is practiced
- •-Sexually active man with a partner of child-bearing potential (pre-menopausal, not surgically sterile) who is not using adequate contraceptive measures, as described above
- •-Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit
- •-Use of any prior and concomitant therapy which may interfere with the objective of the study, including drugs that cause photosensitivity or skin pigmentation within 60 days prior to the Screening Visit
- •-Participants assessed as not suitable for the study in the opinion of the Investigator
研究者
相似试验
进行中（未招募）
1 期
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-UVB Light Alone in the Treatment of VitiligoVitiligoMedDRA version: 21.1Level: PTClassification code: 10047642Term: Vitiligo Class: 100000004858CTIS2023-507470-40-00Clinuvel Inc.200
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001803-17-GBGilead Sciences Inc.52
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19EUCTR2020-001803-17-ITGILEAD SCIENCES INCORPORATED52
进行中（未招募）
1 期
A study to examine the efficacy of KRN23 on bone qualityEUCTR2015-001775-41-FRltragenyx Pharmaceutical Inc.10
进行中（未招募）
1 期
A study to examine the efficacy of KRN23 on bone qualityXLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphate reabsorption in the kidney. Chronic low serum phosphorus levels lead to defective bone mineralization and, consequently, to rickets in children and osteomalacia in adults, the two major pathologic outcomes of the hypophosphatemia.MedDRA version: 19.0 Level: LLT Classification code 10016206 Term: Familial hypophosphataemic rickets System Organ Class: 100000004850EUCTR2015-001775-41-DKltragenyx Pharmaceutical Inc.14